Novartis’s push into oncology and liver disease, two of its treatment priorities, advanced on Monday as the Swiss drugmaker won a second U.S. breakthrough tag for its cancer gene therapy while striking a separate pact with Allergan. The Basel-based drugmaker’s chimeric antigen receptor therapy (CAR-T) treatment, called CTL019, was awarded the U.S. Food and Drug…
Roche to Start New Trial of AC Immune Drug Against Alzheimer’s
Roche is starting a second late-stage trial of investigational Alzheimer’s drug crenezumab that it is developing with Swiss biotech AC Immune, shrugging off failures of similar drugs against the memory-robbing disease. Roche’s new Phase III trial will recruit 750 patients with prodromal or mild Alzheimer’s disease, AC Immune said on Tuesday. An ongoing Phase III,…